Literature DB >> 1519963

Occurrence of suppurative lymphadenitis after a change of BCG vaccine.

P Hengster1, J Schnapka, M Fille, G Menardi.   

Abstract

BCG vaccines are the oldest vaccines in use today, but the protective effect of the vaccination is still controversial. The risk of contracting tuberculosis is low compared with the possible complications after this vaccination. In Austria the formerly used BCG vaccine was not available in the required amount and another vaccine was released by the drug authorities. This product, with a more virulent strain, was used between August and December 1990, and this increased the incidence of complications. Eighty four of 1950 vaccinated newborn babies developed severe suppurative lymphadenitis three to 28 weeks after the vaccination, and surgical treatment was found to be necessary. Isoniazid treatment did not prove to be successful when the lymph node exceeded a certain size. Culture was successful in 46% up to week 20; after 20 weeks no culture became positive. All cultured bacteria were isoniazid sensitive. The question of general vaccination is raised and several points were considered before we came to the conclusion that except for high risk groups a general vaccination programme for neonates is not justified in Western countries.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1519963      PMCID: PMC1793849          DOI: 10.1136/adc.67.7.952

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  17 in total

1.  Bacillus Calmette-Guérin immunization in infants born to HIV-1-seropositive mothers.

Authors:  S Lallemant-Le Coeur; M Lallemant; D Cheynier; S Nzingoula; J Drucker; B Larouze
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

2.  Suppurative lymphadenitis in newborn babies after change of BCG vaccine.

Authors:  P Hengster; M Fille; G Menardi
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

3.  Comparative trial of administration of half (0.05 mg) and quarter (0.025 mg) dose of intradermal Pasteur BCG on 291 infants from birth to 1 year in French Guyana.

Authors:  L Teulieres; M A Diouf; P Chaud; A Saint-Cyr; P Saliou
Journal:  Vaccine       Date:  1991-07       Impact factor: 3.641

4.  Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety.

Authors:  J B Milstien; J J Gibson
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

5.  [Regional suppurative lymphadenitis after BCG vaccination (author's transl)].

Authors:  W Brehmer; N Falkenberg; H Hussels; H S Otto; H Preussler; J Waldschmidt
Journal:  Dtsch Med Wochenschr       Date:  1977-09-02       Impact factor: 0.628

6.  A case-control study to evaluate the effectiveness of mass neonatal BCG vaccination among Canadian Indians.

Authors:  T K Young; E S Hershfield
Journal:  Am J Public Health       Date:  1986-07       Impact factor: 9.308

7.  [BCG vaccination of the newborn infant with the 131 Copenhagen strain].

Authors:  U Stephan; H Haupt; R Scheier; A Nada; U Grimrath; H G Schmitt
Journal:  Klin Padiatr       Date:  1986 Jul-Aug       Impact factor: 1.349

8.  [Tuberculin reaction and the extent of the vaccination scar following BCG vaccination in newborn infants].

Authors:  U Bollag; E Bollag-Albrecht
Journal:  Schweiz Med Wochenschr       Date:  1988-07-02

9.  The protective effect of BCG vaccination of the newborn against childhood tuberculosis in an African community.

Authors:  O Tidjani; A Amedome; H G ten Dam
Journal:  Tubercle       Date:  1986-12

10.  Protective effect of BCG vaccination in infant Asians: a case-control study.

Authors:  G E Packe; J A Innes
Journal:  Arch Dis Child       Date:  1988-03       Impact factor: 3.791

View more
  10 in total

1.  BCG vaccination-induced suppurative lymphadenitis: four signs to pay attention to.

Authors:  Sang Oon Baek; Hyo Sun Ko; Hyun Ho Han
Journal:  Int Wound J       Date:  2017-04-19       Impact factor: 3.315

2.  The Adverse Events, Signs, and Management of Neonatal Bacillus Calmette-Guérin Vaccine Overdose.

Authors:  Ali Abdullah Al-Maqbali; Amal Saif Suliman Al-Maani
Journal:  Oman Med J       Date:  2016-07

3.  Regional lymphadenitis following BCG vaccination.

Authors:  C Merry; R J Fitzgerald
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

4.  Characterization of Mycobacterium bovis BCG vaccines by DNA fingerprinting by a standardized methodology.

Authors:  S C Arya
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

Review 5.  Technologies to improve immunisation safety.

Authors:  C J Clements; M T Aguado; L Jódar
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Different transcriptional profiles of human monocyte-derived dendritic cells infected with distinct strains of Mycobacterium tuberculosis and Mycobacterium bovis bacillus Calmette-Guérin.

Authors:  Nunzia Sanarico; Alessia Colone; Manuela Grassi; Viviana Speranza; Daniela Giovannini; Antonio Ciaramella; Vittorio Colizzi; Francesca Mariani
Journal:  Clin Dev Immunol       Date:  2011-03-22

7.  Management and outcome of Bacille Calmette-Guérin vaccine adverse reactions.

Authors:  Aishwarya Venkataraman; Michael Yusuff; Susan Liebeschuetz; Anna Riddell; Andrew J Prendergast
Journal:  Vaccine       Date:  2015-08-12       Impact factor: 3.641

8.  Increase in Lymphadenitis Cases after Shift in BCG Vaccine Strain.

Authors:  Giorgi Kuchukhidze; Ana Kasradze; Tamar Dolakidze; David Baliashvili; Tsira Merabishvili; Henry M Blumberg; Russell R Kempker
Journal:  Emerg Infect Dis       Date:  2015-09       Impact factor: 6.883

9.  Molecular confirmation of Bacillus Calmette Guerin vaccine related adverse events among Saudi Arabian children.

Authors:  Sahal Al-Hajoj; Ziad Memish; Naila Abuljadayel; Raafat AlHakeem; Fahad AlRabiah; Bright Varghese
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

10.  Nonclinical Development of BCG Replacement Vaccine Candidates.

Authors:  Kamalakannan Velmurugan; Leander Grode; Rosemary Chang; Megan Fitzpatrick; Dominick Laddy; David Hokey; Steven Derrick; Sheldon Morris; David McCown; Reginald Kidd; Martin Gengenbacher; Bernd Eisele; Stefan H E Kaufmann; John Fulkerson; Michael J Brennan
Journal:  Vaccines (Basel)       Date:  2013-04-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.